查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931192

細胞療法生物製造市場按製造模式、治療領域、製程步驟、細胞類型和最終用戶分類，全球預測（2026-2032年）

Cell Therapy Biomanufacturing Market by Manufacturing Model, Therapy Area, Process Stage, Cell Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞療法生物製造市場規模將達到 84.6 億美元，到 2026 年將成長至 97.5 億美元，複合年成長率為 16.46%，到 ​​2032 年將達到 246 億美元。

關鍵市場統計數據
基準年 2025 84.6億美元
預計年份：2026年 97.5億美元
預測年份 2032 246億美元
複合年成長率 (%) 16.46%

生物製造領域的領導者需要緊急行動起來，將實驗室層級的細胞療法進展轉化為可靠、符合監管規定的生產生態系統。

細胞治療生物製造領域正迅速成熟，融合了科學創新、程式工程和臨床需求。隨著開發平臺的不斷演進，企業面臨的挑戰日益嚴峻，即如何將實驗室規模的成功轉化為可重複、合規的生產運營，以滿足患者的需求。這種轉變不僅僅是規模化生產的挑戰；它需要重新思考製程架構、品質系統和商業模式，以協調活細胞產品的生物學複雜性與工業生產的一致性以及監管要求。

技術進步、分散式處理趨勢和策略聯盟如何重塑細胞療法生產和商業化策略

細胞療法生物製造正經歷一場變革浪潮，其驅動力來自技術突破、不斷變化的監管要求以及新型商業模式。自動化、封閉式系統處理和一次性技術的進步降低了人工干預和污染風險，而分析技術和數位化製程控制則實現了對關鍵品質屬性的嚴格監控。同時，基因編輯、細胞工程和冷凍保存技術的創新正在拓展製造平台必須應對的治療方法，促使人們重新評估資本投資和技術藍圖。

評估2025年關稅調整對細胞療法供應鏈、籌資策略和製造地的綜合營運和策略影響。

預計於2025年實施或生效的關稅調整，加劇了細胞療法生物製造領域現有供應鏈的複雜性，其累積影響遠不止於成本上漲。關鍵原料、一次性組件和專用設備的進口關稅，即時對上游工程價格構成壓力，進而影響籌資策略和庫存管理政策。因此，製造商正在重新評估供應商多元化、近岸外包方案以及緩衝庫存政策，以應對成本波動，同時確保供應的連續性。

詳細的細分分析揭示了製造模式、治療方法、製程階段、最終用戶和細胞類型如何驅動不同的營運重點和策略選擇。

對市場細分細微差別的分析表明，生產模式、治療領域、最終用戶、製程階段和細胞類型各自構成不同的營運和商業需求。基於生產模式，市場可細分為「異體移植」（包括現成平台和通用供體架構）和「自體移植」（涵蓋從分散式處理到患者特異性工作流程）。這些差異會影響資本密集度、週期時間敏感度和品管策略。現成產品強調規模化生產和製程標準化，而病患特異性產品則需要客製化低溫運輸、物流和快速釋放檢測。

美洲、歐洲、中東和非洲以及亞太地區的製造業投資、監管多樣性和供應鏈策略的區域觀點

區域趨勢在細胞治療生物製造領域的技術採納、監管參與和供應鏈設計方面發揮關鍵作用。美洲地區擁有強勁的轉化研究動能、成熟的契約製造生態系統以及強調嚴格臨床數據和品質系統的法規環境。這些條件促進了集中資本投資以及生物技術公司與契約製造之間的創新夥伴關係。另一方面，歐洲、中東和非洲地區（EMEA）的情況則更為複雜，各司法管轄區的監管環境存在差異，並且更加重視報銷依據和真實世界數據。跨境生產合作也十分普遍，旨在利用專業知識，同時控制成本並確保合規。

開發商、合約研發生產機構 (CDMO) 和技術供應商如何協調營運整合、策略夥伴關係和平台投資以獲得競爭優勢

細胞治療價值鏈上的各家公司正在採取差異化策略來應對複雜性並加速商業化進程。成熟的研發企業正日益將上游工程最佳化與下游的純化、填充和包裝能力相結合，以減少交接環節並縮短研發週期；而新興企業則傾向於依賴策略性外包來獲取專業的生產能力和合規基礎設施。合約研發生產機構（CDMO）正從純粹的交易服務提供者轉型為提供製程開發專業知識、模組化生產平台和規模化生產技術的策略合作夥伴。

經營團隊切實可行的策略步驟，才能讓產品設計、可擴展製造和供應鏈韌性保持一致，以實現商業性成功？

為確保細胞療法的供應可靠、合規且經濟高效，產業領導者應優先採取一系列切實可行的措施，使科學創新與產業現實相契合。首先，將可製造性評估納入臨床前和早期臨床項目，可使產品設計從研發早期階段就與生產可行性相匹配，從而減少返工並加速向常規生產的過渡。其次，採用模組化、可擴展的製程架構，允許在不中斷檢驗的工作流程的情況下逐步擴大產能，從而確保即使需求和產品種類發生變化，也能維持品質的連續性。

我們採用了嚴謹的混合調查方法，結合訪談、監管審查、供應鏈映射和情境分析，以檢驗我們的實踐發現。

我們的研究途徑結合了定性和定量方法，以獲得可靠且檢驗的研究結果，這些結果反映了實際營運和策略需求。主要研究包括對研發、生產和供應部門的高階領導進行結構化訪談，以及與監管專家和臨床生產從業人員進行引導式討論​​。這些對話讓我們深入了解了實際流程的限制因素、技術採用的促進因素，以及跨多個地點進行技術轉移和驗證所面臨的實際挑戰。

策略整合強調，整合可製造性、供應鏈韌性和區域監管完整性對於將細胞療法帶給患者至關重要。

總之，要將細胞療法從實驗室創新發展到可靠的患者供應，需要的不僅僅是技術突破。它還需要一套整合的營運策略，涵蓋生產方法、製程成熟度、供應鏈韌性以及區域監管現實。那些積極將產品設計與可製造性相結合、投資模組化和自動化流程並建立策略夥伴關係的企業，將能夠更有效地應對活細胞產品固有的複雜性。此外，隨著行業的擴張，適應不斷變化的貿易政策和區域趨勢的能力將成為至關重要的競爭優勢。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依製造模式分類的細胞療法生物製造市場

  • 同種異體移植
    • 現成的模具
    • 通用捐贈平台
  • 自有住房
    • 分散式處理
    • 患者特異性工作流程

9. 按治療領域分類的細胞療法生物製造市場

  • 自體免疫疾病
  • 循環系統
  • 神經系統疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤
  • 整形外科

第10章：依製程階段分類的細胞療法生物製造市場

  • 冷凍保存
  • 下游工藝
    • 配方
    • 收集/淨化
  • 填充和表面處理工程
  • 上游工程
    • 細胞培養擴增
    • 細胞分離

11. 依細胞類型分類的細胞療法生物製造市場

  • 樹突細胞療法
  • 造血幹細胞
  • 誘導性多功能幹細胞
  • 間質幹細胞
    • 脂肪衍生的
    • 骨髓來源
    • 臍帶來源
  • 自然殺手細胞療法
  • T細胞療法
    • CAR-T
    • TCR T細胞療法

第12章 細胞療法生物製造市場（按最終用戶分類）

  • 學術研究機構
  • 合約開發和製造組織
  • 醫院
  • 製藥和生物技術公司

第13章 細胞療法生物製造市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 細胞療法生物製造市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國細胞療法生物製造市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國細胞療法生物製造市場

第17章：中國細胞治療生物製造市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Asahi Kasei Corporation
  • bluebird bio, Inc.
  • Bristol Myers Squibb Company
  • Catalent, Inc.
  • Celgene Corporation
  • Cellectis SA
  • Charles River Laboratories International, Inc.
  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Gilead Sciences, Inc.
  • Hitachi Chemical Co., Ltd.
  • Intellia Therapeutics, Inc.
  • Johnson & Johnson
  • Kite Pharma
  • Lonza Group Ltd.
  • Merck KGaA
  • MilliporeSigma
  • Novartis AG
  • Precision BioSciences, Inc.
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-7B550E008DAC

The Cell Therapy Biomanufacturing Market was valued at USD 8.46 billion in 2025 and is projected to grow to USD 9.75 billion in 2026, with a CAGR of 16.46%, reaching USD 24.60 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.46 billion
Estimated Year [2026] USD 9.75 billion
Forecast Year [2032] USD 24.60 billion
CAGR (%) 16.46%

An urgent orientation for biomanufacturing leaders to transform laboratory cell therapy advances into reliable, regulatory-ready manufacturing ecosystems

The cell therapy biomanufacturing landscape is rapidly maturing at the intersection of scientific innovation, process engineering, and clinical demand. As development pipelines progress, organizations are increasingly required to convert laboratory-scale success into reproducible, compliant manufacturing operations that meet patient needs. This transition is not merely a scale-up challenge; it requires rethinking process architectures, quality systems, and commercial models to reconcile the biologic complexity of living cell products with industrial consistency and regulatory expectations.

Consequently, executives and technical leaders must align decisions across product design, supply chain configuration, and manufacturing footprint to ensure clinical agility and operational resilience. In practice, this means evaluating whether to pursue centralized, high-volume production for allogeneic formats or decentralized, patient-proximate workflows for autologous therapies. It also entails integrating automation where appropriate, strengthening cold chain capabilities, and preparing for regulatory scrutiny on critical quality attributes and release assays. By recognizing these systemic imperatives early, organizations can reduce downstream risk and accelerate the path from clinical proof-of-concept to sustainable commercial supply.

How technological advances, decentralized processing trends, and strategic partnerships are reshaping cell therapy manufacturing and commercial strategies

Cell therapy biomanufacturing is experiencing transformative shifts driven by technological breakthroughs, evolving regulatory expectations, and new commercial models. Advances in automation, closed-system processing, and single-use technologies are reducing manual intervention and contamination risk, while analytics and digital process control enable tighter monitoring of critical quality attributes. At the same time, innovations in gene editing, cell engineering, and cryopreservation are expanding the therapeutic modalities that manufacturing platforms must accommodate, prompting a re-evaluation of capital investments and technology roadmaps.

Moreover, the industry is witnessing a strategic recalibration of manufacturing models. Allogeneic approaches are incentivizing investments in scale and platform standardization to support off-the-shelf availability, whereas autologous therapies are pushing toward decentralized or hub-and-spoke models that prioritize speed and patient proximity. In parallel, partnerships between developers, contract manufacturers, and specialized suppliers are becoming more strategic and integrated, enabling end-to-end solutions that combine clinical expertise with operational capacity. These shifts are reshaping how organizations plan capacity, allocate R&D budgets, and negotiate regulatory pathways, and they require leaders to adopt flexible strategies that accommodate both current program needs and next-generation modalities.

Assessing the compound operational and strategic consequences of 2025 tariff adjustments on supply chains, procurement strategies, and manufacturing footprints in cell therapy

Tariff adjustments implemented or anticipated in 2025 have compounded existing supply chain complexities for cell therapy biomanufacturing, with cumulative effects that reach beyond simple cost increases. Import duties on critical raw materials, single-use components, and specialized equipment create immediate upstream price pressure that can influence sourcing strategies and inventory policies. Consequently, manufacturers are reassessing supplier diversity, nearshoring alternatives, and buffer stock policies to preserve continuity of supply while managing cost volatility.

In addition, tariffs have accelerated structural adjustments in procurement and manufacturing footprints. For some organizations, the tariff environment has justified investments in domestic capacity or closer regional partners to mitigate exposure to trade frictions. For others, the tariffs have driven closer collaboration with suppliers to redesign components or substitute materials where regulatory and product quality constraints allow. From a regulatory and compliance standpoint, tariff-driven reshoring can introduce new validation and regulatory notification requirements that must be anticipated early. Ultimately, the cumulative impact of tariff measures manifests as higher operational complexity, a renewed focus on supply chain resilience, and a strategic premium on flexibility in sourcing and manufacturing location decisions.

Detailed segmentation analysis revealing how manufacturing model, therapy modality, process stage, end user, and cell type drive divergent operational priorities and strategic choices

A nuanced view of market segmentation highlights how manufacturing model, therapy area, end user, process stage, and cell type each shape distinct operational and commercial imperatives. Based on manufacturing model, the market divides into allogeneic approaches, which include off-the-shelf platforms and universal donor architectures, and autologous approaches, which span decentralized processing and patient-specific workflows. These distinctions influence capital intensity, cycle time sensitivity, and quality control strategies, with off-the-shelf products favoring scale and process standardization while patient-specific products demand bespoke cold chain, logistics, and rapid release assays.

Therapy area segmentation shows diverse demands across autoimmune, cardiovascular, neurological, oncology, and orthopedic indications, with oncology further distinguished by hematologic malignancy programs and solid tumor approaches. Each therapeutic focus imposes different potency, dosing, and delivery challenges that must be reconciled with manufacturing capabilities. Based on end user, variation emerges among academic research institutes, contract development and manufacturing organizations, hospitals, and pharmaceutical and biotechnology companies; additionally, hospital settings include hospital-based processing labs and specialty treatment centers, reflecting differing regulatory supervision and throughput expectations. Process stage segmentation differentiates cryopreservation, downstream processing, fill-finish, and upstream processing, where cryopreservation comprises freeze-thaw optimization and storage, downstream processing includes formulation and harvesting purification, and upstream processing includes cell culture expansion and cell separation. Finally, cell type segmentation captures Dendritic Cell Therapy, Hematopoietic Stem Cell, Induced Pluripotent Stem Cell, Mesenchymal Stem Cell, Natural Killer Cell Therapy, and T Cell Therapy, with mesenchymal cells further defined by adipose, bone marrow, and umbilical cord sources and T cell therapy encompassing CAR T and TCR T modalities. Collectively, these intersecting segmentations create distinct value chain requirements that influence technology choices, regulatory approaches, and partnership strategies across the industry.

A regional perspective on manufacturing investment, regulatory diversity, and supply chain strategies across the Americas, Europe Middle East Africa, and Asia Pacific

Regional dynamics play a critical role in shaping technology adoption, regulatory interaction, and supply chain design for cell therapy biomanufacturing. In the Americas, there is strong momentum in translational research, an established contract manufacturing ecosystem, and a regulatory environment that emphasizes rigorous clinical data and quality systems; these conditions favor both centralized capacity investments and innovative partnerships between biotechs and contract manufacturers. In contrast, Europe, Middle East & Africa present a heterogeneous landscape where regulatory frameworks vary by jurisdiction, there is a growing emphasis on reimbursement evidence and real-world data, and cross-border manufacturing collaborations are common to leverage specialized capabilities while managing cost and compliance.

Asia-Pacific is characterized by rapidly expanding clinical activity, increasing manufacturing investment, and government-led initiatives to build domestic biomanufacturing capacity and talent. This region's focus on scaling production and building local supply chains has incentivized both multinational investment and indigenous technology development, creating new options for sourcing and regional manufacturing hubs. Across regions, differences in labor costs, regulatory timelines, and reimbursement policy mean that manufacturing strategies must be tailored to local conditions while preserving global consistency for product quality and regulatory compliance. Therefore, regional insights should inform decisions about where to locate capacity, how to structure logistics, and which partnerships to pursue for market access and operational resilience.

How developers, CDMOs, and technology suppliers are aligning operational integration, strategic partnerships, and platform investments to gain competitive advantage

Companies operating across the cell therapy value chain are adopting differentiated strategies to manage complexity and accelerate commercialization. Established developers are increasingly integrating upstream process optimization with downstream purification and fill-finish capabilities to reduce handoffs and shorten timelines, while emerging firms often rely on strategic outsourcing to access specialized capacity and compliance infrastructure. Contract development and manufacturing organizations are evolving from transactional service providers into strategic partners that contribute process development expertise, modular manufacturing platforms, and scale-up knowledge.

Equipment and consumables suppliers are also reshaping their offerings to support reproducibility and scalability, investing in closed systems, automation solutions, and analytics that facilitate consistent manufacturing across sites. Additionally, collaboration between clinical centers and manufacturing organizations is becoming more formalized, driven by the need to align clinical protocols with manufacturing constraints and to secure patient access pathways. Investors and corporate development teams are prioritizing assets and partnerships that reduce technical risk and create defensible operational advantages, such as proprietary manufacturing platforms or validated, repeatable workflows that can be transferred across geographies. This competitive environment rewards organizations that can combine technical excellence with flexible commercial models and proven regulatory execution.

Practical strategic moves executives should implement to align product design, scalable manufacturing, and supply chain resilience for commercial success

Industry leaders should prioritize a set of actionable moves that reconcile scientific innovation with industrial reality to achieve reliable, compliant, and cost-effective supply for cell therapies. First, align product design with manufacturing feasibility early in development by embedding manufacturability assessments into preclinical and early clinical programs; this reduces rework and accelerates pathway to routine production. Second, adopt modular and scalable process architectures that enable incremental capacity expansion without disrupting validated workflows, thereby maintaining quality continuity as demand and product variants evolve.

Third, strengthen supply chain resilience by diversifying suppliers for critical raw materials, qualifying regional partners for strategic redundancy, and investing in cold chain visibility and contingency planning. Fourth, pursue strategic partnerships with contract manufacturers and automation suppliers to bridge capability gaps rapidly while transferring knowledge through rigorous tech transfer protocols. Fifth, invest in analytical control strategies and digital process monitoring to enable real-time release paradigms where appropriate and to reduce release cycle time. Finally, proactively engage with regulators and payers to align on evidence generation plans that support product approval and reimbursement, thereby reducing downstream commercialization risk. Taken together, these steps create an operational foundation that supports both near-term program execution and long-term commercial resilience.

A rigorous mixed-methods research methodology integrating interviews, regulatory review, supply chain mapping, and scenario analysis to validate practical insights

The research approach combined qualitative and quantitative methods to ensure a robust, validated set of findings that reflect operational realities and strategic imperatives. Primary research included structured interviews with senior leaders across developer, manufacturing, and supplier organizations, as well as guided discussions with regulatory experts and clinical manufacturing practitioners. These engagements provided insights into real-world process constraints, technology adoption drivers, and the practicalities of tech transfer and validation across sites.

Secondary research encompassed a thorough review of peer-reviewed literature, regulatory guidance documents, white papers from industry consortia, and publicly available company disclosures to contextualize technological advances and policy shifts. Supply chain mapping identified critical raw material nodes and single-use component dependencies, while scenario analysis examined the operational impact of trade policy changes and regional manufacturing decisions. Findings were triangulated through cross-validation with subject matter experts and case studies to ensure relevance and applicability. The methodology thus blends empirical evidence with strategic scenario planning to produce insights that are actionable for senior decision-makers.

Strategic synthesis emphasizing the imperative to integrate manufacturability, supply chain resilience, and regional regulatory alignment to advance cell therapies to patients

In conclusion, advancing cell therapies from laboratory innovation to reliable patient supply requires more than technical breakthroughs; it demands integrated operational strategies that address manufacturing modality, process maturity, supply chain resilience, and regional regulatory realities. Organizations that proactively align product design with manufacturability, invest in modular and automated processes, and cultivate strategic partnerships will be better positioned to navigate the complexity inherent to living cell products. Furthermore, adapting to trade-policy shifts and regional dynamics will be a defining competency as the industry scales.

As the field continues to evolve, leaders must balance near-term execution demands with long-term platform development, ensuring that investments in capability and capacity are adaptable to successive generations of cell therapies. By following a disciplined approach that combines technical rigor, operational flexibility, and strategic engagement with regulatory and reimbursement stakeholders, organizations can reduce commercialization risk and accelerate patient access to transformative therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Biomanufacturing Market, by Manufacturing Model

  • 8.1. Allogeneic
    • 8.1.1. Off The Shelf
    • 8.1.2. Universal Donor Platform
  • 8.2. Autologous
    • 8.2.1. Decentralized Processing
    • 8.2.2. Patient Specific Workflow

9. Cell Therapy Biomanufacturing Market, by Therapy Area

  • 9.1. Autoimmune
  • 9.2. Cardiovascular
  • 9.3. Neurological
  • 9.4. Oncology
    • 9.4.1. Hematologic Malignancies
    • 9.4.2. Solid Tumors
  • 9.5. Orthopedic

10. Cell Therapy Biomanufacturing Market, by Process Stage

  • 10.1. Cryopreservation
  • 10.2. Downstream Processing
    • 10.2.1. Formulation
    • 10.2.2. Harvesting Purification
  • 10.3. Fill Finish
  • 10.4. Upstream Processing
    • 10.4.1. Cell Culture Expansion
    • 10.4.2. Cell Separation

11. Cell Therapy Biomanufacturing Market, by Cell Type

  • 11.1. Dendritic Cell Therapy
  • 11.2. Hematopoietic Stem Cell
  • 11.3. Induced Pluripotent Stem Cell
  • 11.4. Mesenchymal Stem Cell
    • 11.4.1. Adipose Derived
    • 11.4.2. Bone Marrow Derived
    • 11.4.3. Umbilical Cord Derived
  • 11.5. Natural Killer Cell Therapy
  • 11.6. T Cell Therapy
    • 11.6.1. CAR T
    • 11.6.2. TCR T

12. Cell Therapy Biomanufacturing Market, by End User

  • 12.1. Academic Research Institute
  • 12.2. Contract Development & Manufacturing Organization
  • 12.3. Hospital
  • 12.4. Pharmaceutical Biotechnology Company

13. Cell Therapy Biomanufacturing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Therapy Biomanufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Therapy Biomanufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell Therapy Biomanufacturing Market

17. China Cell Therapy Biomanufacturing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Asahi Kasei Corporation
  • 18.6. bluebird bio, Inc.
  • 18.7. Bristol Myers Squibb Company
  • 18.8. Catalent, Inc.
  • 18.9. Celgene Corporation
  • 18.10. Cellectis S.A.
  • 18.11. Charles River Laboratories International, Inc.
  • 18.12. CRISPR Therapeutics AG
  • 18.13. Editas Medicine, Inc.
  • 18.14. FUJIFILM Diosynth Biotechnologies
  • 18.15. Gilead Sciences, Inc.
  • 18.16. Hitachi Chemical Co., Ltd.
  • 18.17. Intellia Therapeutics, Inc.
  • 18.18. Johnson & Johnson
  • 18.19. Kite Pharma
  • 18.20. Lonza Group Ltd.
  • 18.21. Merck KGaA
  • 18.22. MilliporeSigma
  • 18.23. Novartis AG
  • 18.24. Precision BioSciences, Inc.
  • 18.25. Sartorius AG
  • 18.26. Takara Bio Inc.
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 243. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 244. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 246. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 249. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 250. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 282. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 283. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2032 (USD MILLION)
  • TABLE 285. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2032 (USD MILLION)
  • TABLE 287. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 288. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 289. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2032 (USD MILLION)
  • TABLE 291. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. G7 CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 295. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2032 (USD MILLION)
  • TABLE 296. NATO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO CE